The opinion in support of the decision being entered today was not written
for publication and is not binding precedent of the Board.
Paper No. 17
UNITED STATES PATENT AND TRADEMARK OFFICE
__________
BEFORE THE BOARD OF PATENT APPEALS
AND INTERFERENCES
__________
Ex parte JEAN-YVES MARCEL PAUL BONNEFOY
___________
Appeal No. 2000-1783
Application No. 08/817,719
__________
ON BRIEF
__________
Before SCHEINER, ADAMS and GRIMES, Administrative Patent Judges.
SCHEINER, Administrative Patent Judge.
DECISION ON APPEAL
This is an appeal under 35 U.S.C. ' 134 from the final rejection of claims 14-26,
the only claims remaining in the application.
Claims 14, 15, 18, 19 and 21 are representative of the subject matter on appeal
and read as follows:
14. A method of treating an autoimmune disorder comprising administering to a
patient in need of such treatment an amount of an agent that binds CD23, and thereby
blocks the interaction of CD23 with a ligand to which CD23 binds in vivo, sufficient to
effect such treatment.
15. The method according to claim 14 wherein said agent is an antibody.
18. The method according to claim 14 wherein said ligand is CD21, CD11b
or CD11c.
19. The method according to claim 14 wherein said autoimmune disorder is
rheumatoid arthritis.
21. The method according to claim 14 wherein said autoimmune disorder is
arthritis, lupus erythematosus, systemic lupus erythematosus, Mashimotos thyroiditis,
Page: 1 2 3 4 5 6 7 8 9 10 Next
Last modified: November 3, 2007